• About Us
  • Corporate Profile
  • Management Team
  • Board of Directors
  • Scientific Advisory Board
  • Respiratory and Acute Care Advisory Board
  • Cardiovascular Advisory Board
  • Immunology Advisory Board
  • Investors
• Products
• Research
  • sPLA2 - What is it?
  • Respiratory and Acute Care Program
  • sPLA2 in SCD
  • IMPACTS Trial Site
  • Scientific Advisory Board
  • Cardiovascular Program
  • sPLA2 in CVD
  • FRANCIS Trial Site
  • PLASMA Trial Site
  • PLASMA 2 Trial Site
  • Scientific Advisory Board
  • Immunology Program
  • A-623 in SLE and Autoimmune Diseases
  • Scientific Advisory Board
  • Preclinical Programs
  • Glossary
  • References
• News & Media
• Careers
• Contact Us

<< Return to Board of Directors

Donald J. Santel‚ Director

Donald J. Santel has 25 years experience in the biotechnology/biopharmaceutical and medical device industries. Most recently, he was Co-Founder and Chief Executive Officer at CoTherix, Inc., where he launched Ventavis® Inhalation Solution and led the sale of the company to Actelion Pharmaceuticals, Ltd. in January 2007. Prior to CoTherix, he served as President and Chief Operating Officer of Reflow, and sold the company to Fox Hollow (now EV3) and served as Vice President of Marketing and International Sales at Cardiac Pathways Corporation, a medical device company later acquired by Boston Scientific. Mr. Santel began his career at Medtronic, Inc. Mr. Santel also serves on the board of Hyperion Therapeutics. He has a BSE from Purdue University and an MS in from the University of Minnesota.